Cubist Systematic Strategies LLC Sells 41,264 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)

Cubist Systematic Strategies LLC lessened its position in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Rating) by 12.4% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 290,272 shares of the biotechnology company’s stock after selling 41,264 shares during the period. Cubist Systematic Strategies LLC’s holdings in Viking Therapeutics were worth $790,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the company. Quantum Private Wealth LLC increased its holdings in Viking Therapeutics by 8.8% during the 2nd quarter. Quantum Private Wealth LLC now owns 50,548 shares of the biotechnology company’s stock worth $146,000 after purchasing an additional 4,100 shares in the last quarter. Cornerstone Capital Inc. grew its holdings in shares of Viking Therapeutics by 3.5% in the 3rd quarter. Cornerstone Capital Inc. now owns 143,980 shares of the biotechnology company’s stock valued at $392,000 after acquiring an additional 4,840 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Viking Therapeutics by 20.5% in the 1st quarter. JPMorgan Chase & Co. now owns 32,893 shares of the biotechnology company’s stock valued at $99,000 after acquiring an additional 5,606 shares in the last quarter. Blair William & Co. IL grew its holdings in shares of Viking Therapeutics by 4.2% in the 1st quarter. Blair William & Co. IL now owns 159,717 shares of the biotechnology company’s stock valued at $479,000 after acquiring an additional 6,454 shares in the last quarter. Finally, ExodusPoint Capital Management LP grew its holdings in shares of Viking Therapeutics by 26.9% in the 3rd quarter. ExodusPoint Capital Management LP now owns 30,753 shares of the biotechnology company’s stock valued at $84,000 after acquiring an additional 6,512 shares in the last quarter. Institutional investors own 34.71% of the company’s stock.

Viking Therapeutics Stock Performance

Shares of NASDAQ:VKTX opened at $11.00 on Friday. Viking Therapeutics, Inc. has a 52-week low of $2.02 and a 52-week high of $11.98. The company has a market capitalization of $862.62 million, a P/E ratio of -12.09 and a beta of 0.77. The company has a 50-day simple moving average of $9.82 and a 200 day simple moving average of $6.04.

Viking Therapeutics (NASDAQ:VKTX – Get Rating) last issued its earnings results on Wednesday, February 8th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.03). As a group, equities analysts forecast that Viking Therapeutics, Inc. will post -0.95 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on VKTX. Oppenheimer raised their price objective on Viking Therapeutics from $17.00 to $20.00 in a report on Thursday, February 23rd. Maxim Group raised their price objective on Viking Therapeutics from $10.00 to $15.00 and gave the company a “buy” rating in a report on Monday, December 19th. StockNews.com cut Viking Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, March 2nd. Raymond James raised their price objective on Viking Therapeutics from $11.00 to $12.00 and gave the company an “outperform” rating in a report on Thursday, February 9th. Finally, HC Wainwright restated a “buy” rating and issued a $21.00 price objective on shares of Viking Therapeutics in a report on Thursday, February 9th.

Viking Therapeutics Profile

(Get Rating)

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.